公开(公告)号：US20230310561A1

公开(公告)日：2023-10-05

申请号：US18023573

申请日：2021-09-07

Applicant: OSAKA UNIVERSITY

Inventor： Hironori NAKAGAMI ,  Ryuichi MORISHITA ,  Shuko TAKEDA ,  Hiroki HAYASHI

IPC: A61K39/00 ,  A61P25/28

CPC classification number: A61K39/0005 ,  A61P25/28 ,  A61K2039/6031 ,  A61K2039/575

Abstract: The present invention provides an immunogenic composition comprising an antigenic peptide and a carrier protein, wherein the antigenic peptide is capable of eliciting production of an antibody against a phosphorylated tau protein and is a human tau protein fragment containing (1) YSpSPGpSPG (SEQ ID NO: 2), (2) AKpSpTPpTAE (SEQ ID NO: 5), (3) AKpSpTPTAE (SEQ ID NO: 31), (4) AKpSTPpTAE (SEQ ID NO: 32), (5) AKSpTPpTAE (SEQ ID NO: 33), or (6) IVpYKpSPV (SEQ ID NO: 24).

公开(公告)号：US20250057928A1

公开(公告)日：2025-02-20

申请号：US18717944

申请日：2022-12-07

Applicant: OSAKA UNIVERSITY ,  FunPep Co., Ltd.

Inventor： Hironori NAKAGAMI ,  Hiroki HAYASHI ,  Ryuichi MORISHITA ,  Makoto SAKAGUCHI ,  Sotaro KAWABATA

IPC: A61K39/00 ,  A61K47/62

Abstract: The present invention provides a vaccine composition containing a complex of a T cell receptor antigen peptide and a B cell receptor antigen peptide and capable of inducing the production of an antibody against IL-23, wherein the B cell receptor antigen peptide is represented by the following formula (I): X1-X2-X3-X4-X5-X6-X7-X8   (I) wherein X1 is S, A, G, T, K, or R, X2 is P, A, G, S, T, K, or R, X3 is S, A, G, T, K, or R, X4 is Q, A, G, T, or N, X5 is P, A, G, S, T, Q, or N, X6 is W, A, Y, or E, X7 is Q, A, G, T, or N, and X8 is R, A, G, or K.

公开(公告)号：US20240002510A2

公开(公告)日：2024-01-04

申请号：US17848983

申请日：2022-06-24

Applicant: Chugai Seiyaku Kabushiki Kaisha ,  Osaka University

Inventor： Hitoshi KATADA ,  Kanako TATSUMI ,  Yutaka MATSUDA ,  Shun SHIMIZU ,  Masaki KAMIMURA ,  Yasunori KOMORI ,  Yuji HORI ,  Tomoyuki IGAWA ,  Hiroki KAWAUCHI ,  Hiroki HAYASHI ,  Hiroaki SUSUMU ,  Shimon SAKAGUCHI

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  A61K2039/505

Abstract: The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.

公开(公告)号：US20230330214A1

公开(公告)日：2023-10-19

申请号：US18028613

申请日：2021-09-30

Applicant: OSAKA UNIVERSITY ,  TAKARA BIO INC. ,  ANGES, INC.

Inventor： Hironori NAKAGAMI ,  Ryuichi MORISHITA ,  Hiroki HAYASHI ,  Yasunori AMAISHI ,  Sachiko OKAMOTO ,  Junichi MINENO ,  Hisato IKAI ,  Junko MICHIBATA ,  Takao KOMATSUNO

IPC: A61K39/215 ,  A61P37/04

CPC classification number: A61K39/215 ,  A61P37/04 ,  A61K2039/53

Abstract: Provided is DNA that: encodes a coronavirus (SARS CoV-2) spike protein or a fragment thereof; and has been optimized to partially or fully exhibit a codon included in a DNA sequence.